10x Genomics $TXG Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lessened its position in 10x Genomics (NASDAQ:TXG – Free Report) by 49.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 104,030 shares of the company’s stock after selling 103,226 shares during the period. Pictet Asset Management Holding SA’s holdings in 10x Genomics were worth $9,372,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its holdings in shares of 10x Genomics by 29.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 934 shares of the company’s stock worth $84,000 after purchasing an additional 215 shares during the last quarter. GAMMA Investing LLC lifted its holdings in 10x Genomics by 8.7% during the 3rd quarter. GAMMA Investing LLC now owns 4,668 shares of the company’s stock valued at $422,000 after purchasing an additional 374 shares during the last quarter. Arizona State Retirement System lifted its holdings in 10x Genomics by 1.5% during the 2nd quarter. Arizona State Retirement System now owns 29,223 shares of the company’s stock valued at $1,120,000 after purchasing an additional 430 shares during the last quarter. Carolina Wealth Advisors LLC bought a new position in 10x Genomics during the 3rd quarter valued at about $46,000. Finally, Nisa Investment Advisors LLC lifted its holdings in 10x Genomics by 11.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,239 shares of the company’s stock valued at $564,000 after purchasing an additional 653 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 13,818 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $63.02, for a total transaction of $870,810.36. Following the sale, the insider owned 488,182 shares of the company’s stock, valued at $30,765,229.64. This represents a 2.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John R. Stuelpnagel sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the completion of the sale, the director owned 328,436 shares of the company’s stock, valued at $20,280,923. The trade was a 5.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 190,333 shares of company stock worth $12,604,970 over the last quarter. Corporate insiders own 8.84% of the company’s stock.

Analyst Upgrades and Downgrades

TXG has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of 10x Genomics from $40.00 to $70.00 and gave the company an “equal weight” rating in a research report on Monday, October 12th. Leerink Partners raised their price objective on shares of 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a report on Tuesday, September 29th. Wall Street Zen upgraded shares of 10x Genomics from a “hold” rating to a “buy” rating in a research note on Saturday. Piper Sandler lifted their target price on shares of 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, September 28th. Finally, JPMorgan Chase & Co. reduced their target price on 10x Genomics from $70.00 to $65.00 and set a “neutral” rating on the stock in a report on Monday, November 9th. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $68.40.

Check Out Our Latest Report on 10x Genomics

10x Genomics Stock Performance

10x Genomics stock opened at $58.19 on Monday. The business’s fifty day moving average is $73.92 and its two-hundred day moving average is $42.57. The firm has a market cap of $7.58 billion, a P/E ratio of -111.90 and a beta of 2.03. 10x Genomics has a 52 week low of $15.12 and a 52 week high of $102.81.

10x Genomics (NASDAQ:TXG – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12. 10x Genomics had a negative return on equity of 8.19% and a negative net margin of 10.84%. The company had revenue of $150.67 million during the quarter, compared to analyst estimates of $147.96 million. During the same period last year, the company posted ($0.22) earnings per share. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, equities research analysts predict that 10x Genomics will post -0.74 earnings per share for the current year.

10x Genomics Company Profile

(Free Report)

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Read More

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.